News & Events

Your medical device is ready for the market. The development phase is complete, the technical documentation is progressing, and your team expects the CE marking process to move forward smoothly. Then comes the most challenging part: clinical evaluation of medical devices. Many manufacturers underestimate how demanding MDR clinical evaluation has become. A weak literature review,… View Article …

Pharmaceutical companies across Europe are increasingly searching for answers to the question: “which vendors support structured product labeling to ePI?” But most organizations are already approaching the problem from the wrong angle. The real challenge is not finding software. The real challenge is surviving the operational complexity that comes with ePI implementation — a challenge… View Article …

Pharmaceutical companies entering the European market often initially struggle to identify a suitably qualified Qualified Person (QP). However, the real challenge begins when they must simultaneously coordinate documentation, importation, GMP compliance, audit readiness, product release timelines, and ongoing GMP consulting support across multiple stakeholders.  In many cases, the process behind obtaining a batch release certificate… View Article …

Many pharmaceutical companies are underestimating how difficult achieving ePI readiness will become once implementation deadlines move closer. What initially appears to be a straightforward compliance initiative often turns into a complex transformation involving regulatory workflows, structured content authoring based on HL7 FHIR standards, multilingual labeling, IT system integration, governance, and lifecycle management. Without a realistic… View Article …

Pharmaceutical companies expanding into Europe often underestimate the complexity of QP batch release once products enter the EU regulatory framework. Under EU GMP Annex 16, every medicinal product batch released to the European market must be certified by a Qualified Person before distribution can legally occur. This requirement applies regardless of whether the product is… View Article …

If you are looking for a medical device regulatory consultant, the situation is usually already serious. Deadlines are approaching, MDR requirements keep expanding, notified body expectations are becoming harder to interpret, and your internal teams are struggling to keep regulatory documentation, vigilance obligations, PRRC responsibilities, and quality systems fully aligned. What initially looked manageable often… View Article …

Companies operating in pharma, medical devices, and other regulated industries cannot afford a weak quality system. Regulatory authorities emphasize that companies must maintain robust and sustainable quality systems to ensure continuous GMP compliance and inspection readiness. When deviations, audit findings, missing documentation, CAPA failures, or inspection observations begin to accumulate, the entire business is at… View Article …

Pharmaceutical companies are under increasing pressure to modernize labeling processes and prepare for electronic product information (ePI) requirements. Yet many organizations searching for “recommended tools for structured product labeling updates” quickly discover that selecting the wrong platform can create costly implementation delays, fragmented workflows, compliance risks, and long-term operational inefficiencies. The challenge is no longer… View Article …

Pharmaceutical companies today are surrounded by data—clinical results, safety signals, real-world evidence—yet some of the most valuable opportunities remain hidden in plain sight. Statins are a striking example. For decades, observations of anti-inflammatory and immune-modulating effects were logged as secondary findings and largely set aside. Today, those same signals are driving serious research into statins’… View Article …

Pharma companies across the EU are facing a growing pressure that many still underestimate. The shift toward ePI requirements is not just another regulatory update, but a fundamental change in how product information must be created, managed and delivered. Under the new legislation, structured electronic product information is becoming a formal requirement, replacing static documents… View Article …

If you are looking for ISO 13485 risk management checklist for medical devices, you are likely not at the beginning—you are already facing pressure. On paper, ISO 13485 risk management seems straightforward: define risks, document them, and demonstrate control. But in practice, it quickly becomes one of the most difficult parts of your entire quality… View Article …

Companies operating in a GMP environment often believe their supply chain is under control – until something goes wrong. A single weak or insufficiently qualified GMP vendor can trigger audit findings, delays, or even product recalls. In regulated industries, vendors are considered an extension of your own operations, meaning their failures directly impact your compliance,… View Article …

The moment your device enters the market, the pressure doesn’t ease—it intensifies. Suddenly, you’re expected to prove, continuously, that your product remains safe and performs as intended in real-world use. That means collecting data, analyzing it, updating documentation, and feeding everything back into your quality and risk systems—again and again, for the entire lifecycle. This… View Article …

If you are searching for how to choose a drug safety consulting partner, it usually means one thing—you are already feeling the pressure of keeping your pharmacovigilance system under control. The problem is that drug safety is not static. It is a continuous process of detecting, assessing, and preventing adverse effects, where even small gaps… View Article …

Most companies don’t feel the problem with CMC at the beginning—it builds silently in the background, hidden behind progress, timelines, and the assumption that everything will “come together” before submission. But CMC doesn’t work that way. Because CMC assessment is not just a final check. It is the foundation that proves your product can be… View Article …

Companies searching for “rank the best training programs for pv teams” usually assume that choosing the right pharmacovigilance training will automatically solve compliance challenges. Investing in pv training feels like a logical, structured step—after all, teams need knowledge, and regulators expect trained personnel. But pharmacovigilance is not just about understanding guidelines; it is a system… View Article …

For every marketing authorization holder (MAH), pharmacovigilance is not just another operational function — it often becomes a constant source of pressure. MAHs are expected to monitor safety, manage risks, and remain inspection-ready at all times, while regulatory expectations continue to grow and evolve. The problem is that most marketing authorization holders quickly find themselves… View Article …

Many companies assume that hiring a RA consultant will immediately bring clarity and control to their regulatory process. On paper, it looks simple: bring in a regulatory affairs consultant, delegate the work, and move forward with confidence. But the reality often looks very different. Regulatory affairs consulting is a highly complex, evolving function that spans… View Article …